Topical fibronectin in the treatment of persistent corneal epithelial defects and trophic ulcers

Am J Ophthalmol. 1987 Nov 15;104(5):494-501. doi: 10.1016/s0002-9394(14)74107-8.


Six patients with persistent corneal epithelial defects that failed to improve with standard therapy were treated with topical fibronectin in a phase I uncontrolled trial. Fibronectin was purified from autologous plasma by affinity chromatography and administered topically, 0.5 mg/ml five times a day, for three weeks. Complete reepithelialization was achieved in five patients: three healed three to 17 days after initiation of treatment while two healed one to two weeks after discontinuation of topical fibronectin. No side effects were observed. Over a follow-up period of three to 18 months, two recurrences were noted.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Topical
  • Aged
  • Cornea / pathology
  • Corneal Diseases / drug therapy*
  • Corneal Diseases / pathology
  • Corneal Diseases / physiopathology
  • Corneal Ulcer / drug therapy
  • Corneal Ulcer / pathology
  • Drug Evaluation
  • Epithelium / pathology
  • Female
  • Fibronectins / administration & dosage
  • Fibronectins / isolation & purification
  • Fibronectins / therapeutic use*
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Recurrence
  • Visual Acuity
  • Wound Healing


  • Fibronectins